Quick Read – ABBV trades at 17x forward earnings despite 12% revenue growth, leaving shares roughly 35% below the 2030 bull case target of $300. – A $744 million IPR&D charge slashed net income 46%, but management raised full-year EPS guidance to $14.28, signaling underlying…
rnings strength. – Reaching $300 requires only modest multiple expansion to 23x, achievable if Skyrizi and Rinvoq sustain 20%+ growth through 2030. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and AbbVie didn’t make the cut. Grab the names FREE today
AbbVie (NYSE:ABBV) has quietly become one of healthcare’s most underrated growth stories. CEO Robert A. Michael told investors after Q1, “We are off to an excellent start in 2026, with first-quarter results exceeding our expectations.” The numbers back him up.
Immunology revenue hit $7.29 billion, with Skyrizi up 30.9% and Rinvoq up 23.3%. Yet shares trade at just $221.59, down 1.43% YTD. Can AbbVie hit $300 by 2030?